FDA Brief

Warning letters Drugs

FDA warning letter to

ketaminetroches.com

High riskIssued Jun 23Posted Jul 7Center for Drug Evaluation and Research (CDER)

FDA warns ketaminetroches.com that it sells unapproved and misbranded ketamine troches to U.S. consumers online.

What happened

FDA reviewed the website www.ketaminetroches.com on February 25, 2026, rather than conducting an inspection. FDA found the site offering "Ketamine Troches" with claims that they treat anxiety and depression, making the product a drug intended for human use. FDA says there is no approved application for this product and its labeling lacks adequate directions for use.

What FDA found

  1. The company sells ketamine troches without an FDA-approved drug application, which the law requires for new drugs.

    FD&C Act sections 301(d) and 505(a) (21 U.S.C. 331(d), 355(a))
  2. Website claims that the troches treat anxiety and depression show the product is a drug intended for human use.

    FD&C Act section 201(g) (21 U.S.C. 321(g)); 21 CFR 201.128
  3. The product's labeling does not give adequate directions for use, so it is misbranded.

    FD&C Act section 502(f)(1) (21 U.S.C. 352(f)(1))
  4. The product is a prescription drug that cannot be used safely without a licensed practitioner's supervision, so a layperson cannot be given adequate directions.

    FD&C Act section 503(b)(1) (21 U.S.C. 353(b)(1)); 21 CFR 201.5
  5. Because the drug is not approved in the United States, it does not qualify for the exemption from adequate-directions labeling.

    21 CFR 201.115(a)
  6. Offering the product for sale to U.S. consumers puts a misbranded drug into interstate commerce.

    FD&C Act section 301(a) (21 U.S.C. 331(a))

What FDA wants

FDA tells the company to stop offering unapproved and misbranded drugs for sale to U.S. consumers and to send a written response with corrective steps and supporting documents to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov, citing reference number MARCS-CMS 725148.

Who should pay attention

  • compounding pharmacies that make or ship ketamine troches
  • telehealth and online sellers of ketamine or psychedelic-adjacent products
  • clinics and brands marketing unapproved drugs directly to patients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk